Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer

Background Influenza is a health risk to children receiving chemotherapy for cancer. An absolute lymphocyte count (ALC) >1,000 cells/mm3 has been associated with the ability to produce an immune response to influenza vaccine during chemotherapy. However, clinical efficacy of influenza vaccination...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2016-11, Vol.63 (11), p.2011-2018
Main Authors: Choi, Daniel K., Fuleihan, Ramsay L., Walterhouse, David O.
Format: Article
Language:English
Subjects:
Adolescent
Cancer
Cell number
Chemotherapy
Child
Child, Preschool
childhood cancer
Children
Cohort Studies
Female
Fever
Health risks
Hematology
Humans
Immune response
Infant
infection prevention
Infections
Influenza
Influenza Vaccines - immunology
Influenza, Human - epidemiology
Lymphocyte Count
Lymphopenia
Male
Morbidity
Neoplasms - drug therapy
Neoplasms - immunology
Oncology
Pediatrics
Prospective Studies
supportive care
Vaccination
Vaccines
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Influenza is a health risk to children receiving chemotherapy for cancer. An absolute lymphocyte count (ALC) >1,000 cells/mm3 has been associated with the ability to produce an immune response to influenza vaccine during chemotherapy. However, clinical efficacy of influenza vaccination during chemotherapy remains unclear. Procedure We conducted a prospective cohort study in children receiving chemotherapy for cancer during two consecutive influenza seasons. Assessments of immune cells and serologic response were measured immediately before and after receiving influenza vaccine. Patients were monitored for influenza or influenza‐like illness (ILI). Results Two hundred fifty‐nine patients were studied over 2 years. The seroresponse rate was 62% (98/157). The median ALC at vaccination was higher in seroresponders than nonresponders, 854 cells/mm3 versus 602 cells/mm3, respectively (P < 0.036). Univariate analysis showed that patients with an ALC
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.26110